Trump’s Drug Price Deals: 3-Year Limit Revealed | STAT

WASHINGTON — When President Trump unveiled his plan to lower prescription drug costs through “most-favored nation” (MFN) deals with pharmaceutical companies, he promised a new era of affordability for American consumers. While the administration touted these agreements as a significant step towards reducing healthcare expenses, details surrounding their implementation and duration remained largely undisclosed. Now, filings with the Securities and Exchange Commission (SEC) are beginning to reveal some specifics: at least some of these deals are structured to last for three years, according to a report from STAT News.

The agreements, initially struck with 16 major drug companies starting in September 2025, aimed to secure lower drug prices for the United States, potentially by encouraging other wealthy nations to pay more. However, a recent analysis by the non-profit 46brooklyn found that despite these deals, all 16 companies still raised the list prices of some of their drugs in early 2026. This raises questions about the immediate impact of the MFN agreements on consumer costs.

The Three-Year Timeline: What the SEC Filings Show

The SEC filings, as reported by STAT, indicate that the three-year duration applies to at least some of the agreements. The specifics of each deal vary between the 16 companies involved, but the common thread of a three-year term provides a clearer picture of the long-term commitment—or lack thereof—embedded within these arrangements. This timeframe is significant because it suggests the effects of the deals may not be fully realized, or may wane, before the end of a presidential term.

The initial wave of deals included agreements with major pharmaceutical players like Pfizer. Pfizer CEO Albert Bourla joined President Trump at the White House in September to announce the company’s participation, but the precise details of their agreement remained confidential. The lack of transparency surrounding these deals has been a consistent point of criticism from both sides of the political spectrum.

Price Increases Despite Agreements: A Complex Picture

The fact that drug companies continued to raise prices in January 2026, even after signing MFN agreements, highlights the complexities of drug pricing. Antonio Ciaccia, CEO of 46brooklyn, noted that January is a common time for pharmaceutical companies to implement price increases, suggesting the timing may not be directly linked to the MFN deals. However, the simultaneous occurrence of price hikes and the MFN agreements raises concerns about the effectiveness of the latter in controlling costs.

The price increases affected a range of medications, including those used to treat cancer, heart failure, and Type 2 diabetes, as well as some COVID-19 vaccines. This broad impact suggests that the MFN deals may not be preventing price increases across the board, but rather shifting them or limiting their scope.

Shifting Priorities at the SEC

The broader regulatory landscape is also undergoing significant changes under the second Trump administration. A recent analysis by Cooley LLP highlights a shift in focus at the Securities and Exchange Commission (SEC) towards rolling back regulations implemented during the Biden administration. This change in priorities could impact the level of scrutiny applied to pharmaceutical companies and their pricing practices, potentially influencing the enforcement of the MFN agreements.

The SEC’s regulatory freeze, initiated through an executive order in January 2025, paused ongoing and recently finalized regulations, signaling a broader effort to reduce regulatory burdens on businesses. This shift could create a more favorable environment for pharmaceutical companies, potentially offsetting some of the cost-saving measures outlined in the MFN agreements.

Understanding “Most Favored Nation” Pricing

The concept of “most favored nation” pricing, borrowed from international trade, aims to ensure that a country receives the lowest price offered by a supplier. In the context of prescription drugs, the Trump administration sought to leverage this principle to negotiate lower prices with pharmaceutical companies, arguing that the United States should not pay more for drugs than other wealthy nations. However, implementing this strategy in the pharmaceutical market has proven challenging due to the complex interplay of factors influencing drug pricing, including research and development costs, market competition, and patent protections.

What Comes Next: Monitoring and Evaluation

The long-term impact of the MFN agreements remains to be seen. Ongoing monitoring of drug prices, coupled with increased transparency regarding the details of the agreements, will be crucial for evaluating their effectiveness. The SEC filings provide a starting point for understanding the duration of these deals, but further investigation is needed to assess their broader implications for consumers and the healthcare system. It is also important to track any changes in SEC regulations that could affect the enforcement of these agreements. The evolving regulatory landscape and the continued price increases suggest that a comprehensive approach to drug pricing reform will be necessary to achieve lasting affordability.